<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337050</url>
  </required_header>
  <id_info>
    <org_study_id>A8471004</org_study_id>
    <nct_id>NCT01337050</nct_id>
  </id_info>
  <brief_title>Asian Phase I Study Of PF-03446962</brief_title>
  <official_title>A Phase I Pharmacokinetic And Pharmacodynamic Study Of Pf-03446962 In Asian Patient With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Asian Phase 1, multi center, open label, single arm study of PF 03446962 with dose
      escalation and designed to define the Maximum Tolerated Dose [MTD] and the Recommended Phase
      2 Dose [RP2D].
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Baseline up to Week 6</time_frame>
    <description>The MTD was defined as the highest dose of PF-03446962 associated with the occurrence of Dose Limiting Toxicities (DLTs) in at most 1 of 6 participants with the next higher dose having at least 2/3 or 2/6 participants experiencing DLTs (that is (i.e.) Maximum Administrated Dose). DLT is defined if the participants meets the following criteria during the first 6 weeks of treatment, possibly attributable to PF-03446962. Neutropenia grade 4 (less than [&lt; ])500/cubic millimeter [mm^ 3]) lasting for greater than equal to (&gt;=) 8 days; Febrile Neutropenia &gt;= Grade 3; Neutropenic Infection &gt;= Grade 3; Grade 4 thrombocytopenia (&lt;25,000/mm^3); Grade 3 thrombocytopenia (&lt;50,000/mm^3) with active bleeding; Grade 3 or higher non-hematological toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase-2 Dose (RP2D)</measure>
    <time_frame>Baseline up to 28 days after last dose of study medication</time_frame>
    <description>RP2D was determined by a comprehensive assessments based on all the safety data, efficacy data, pharmacokinetics profile and biomarker data using blood and tumor samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 28 days after last dose</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious adverse events (non-SAEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity</measure>
    <time_frame>Baseline up to 28 days after last dose</time_frame>
    <description>Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity; Grade 1 (Mild Adverse Event), Grade 2 (Moderate Adverse Event), Grade 3 (Severe Adverse Event), Grade 4 (Life- Threatening or Disabling Adverse Event), Grade 5 (Death Related to Adverse Event).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 28 days after last dose</time_frame>
    <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (non-SAEs). Relatedness to study drug was assessed based on investigator's discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities</measure>
    <time_frame>Baseline up to 28 days after last dose</time_frame>
    <description>Laboratory abnormalities were segregated into hematology, chemistry, coagulation and urinalysis test. It had been graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) into Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Life-threatening). Participants with abnormality of any of these grades are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax)</measure>
    <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Trough Concentration (Cmin)</measure>
    <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to 28 Days [AUC (0-28)]</measure>
    <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
    <description>AUC (0-28)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-28).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) for drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL)</measure>
    <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vd)</measure>
    <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble Proteins Level</measure>
    <time_frame>Baseline, Day 1, 0 hour (H), 6 H Cycle 1 Day 1, Day 22 of Cycle 1, Day 1 Cycle 2, Day 1 Cycle 3 and end of treatment (up to cycle 30)</time_frame>
    <description>Soluble proteins related to Activin Receptor-Like Kinase 1 (ALK-1) signaling and angiogenesis signaling including Vascular adhesion molecule (VAM), Monocyte chemotactic protein 1 (MCP-1), Angiopoietin 2, Tear intercellular adhesive molecule 1 (ICAM-1), Soluble intracellular adhesion molecule 1 (SIAM-1), Soluble vascular adhesion molecule 1 (SVAM-1), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Soluble vascular endothelial growth factor- Receptor 1 (REC 1) (SVEGF-REC 1), Soluble vascular endothelial growth factor- REC 2 (SVEGF-REC 2), Soluble vascular endothelial growth factor- REC 3 (SVEGF-REC 3), Bone morphogenetic protein-9 (BMP-9), Endoglin, Transforming growth factor- beta 1 (TGF- Beta 1), Placental growth factor (PGF) was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Human Anti-Human Antibody (HAHA)</measure>
    <time_frame>Baseline, Post-dose (Day 1 of every Cycle up to 28 days after last dose) up to Cycle 30</time_frame>
    <description>HAHA analysis was performed using validated, sensitive and specific chemiluminescence enzyme-linked immunosorbent assay (ELISA) methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Best Overall Response (BOR)</measure>
    <time_frame>Baseline, thereafter every 6 weeks up to end of treatment (up to Cycle 30)</time_frame>
    <description>Number of participants with best overall response according to Response Evaluation Criteria in Solid Tumors (RECIST); Complete response (CR): disappearance of all lesions, Pathological lymph nodes' reduction in short axis (SA) to less than (&lt;)10 millimeter (mm); Partial response (PR): greater than equal to (&gt;=) 30% decrease in sum of longest dimensions (LD) of Target Lesions (TL) taking reference baseline sum LD; Progressive disease (PD):&gt;=20% (&gt;= 5 mm increase) increase sum of LD of TL taking as a reference smallest sum of LD recorded since treatment start, appearance of &gt;=1 new lesions, unequivocal progression of existing non-TL, or appearance of &gt;=1 new lesion; Stable disease (SD): insufficient shrinkage to qualify for PR, insufficient increase to qualify for PD taking reference smallest sum of the LD since treatment start. Confirmed response=that persist at least 4 weeks after initial documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Benefit Response (CBR)</measure>
    <time_frame>Baseline, thereafter every 6 weeks up to end of treatment (up to Cycle 30)</time_frame>
    <description>Number of participant with clinical benefit response (CBR): CBR was defined as CR, PR, SD &gt;12 weeks, SD&lt;12weeks or PD according to RECIST criteria; Complete response (CR): disappearance of all lesions, Pathological lymph nodes' reduction in short axis (SA) to &lt;10 mm; Partial response (PR): &gt;=30% decrease in sum of longest dimensions (LD) of Target Lesions (TL) taking reference baseline sum LD; Progressive disease (PD):&gt;=20% (&gt;= 5 mm increase) increase sum of LD of TL taking as a reference smallest sum of LD recorded since treatment start, appearance of &gt;=1 new lesions, unequivocal progression of existing non-TL, or appearance of &gt;=1 new lesion; Stable disease (SD): insufficient shrinkage to qualify for PR, insufficient increase to qualify for PD taking reference smallest sum of the LD since treatment start.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline, thereafter every 6 weeks up to end of treatment (up to Cycle 30)</time_frame>
    <description>PFS was defined as the time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Months) = (first event date minus randomization or the first dose date plus 1) divided by 30.44). PFS was calculated using the median, and 95% Confidence Intervals (CIs) and Progressive disease (PD):&gt;=20% (&gt;= 5 mm increase) increase sum of LD of TL taking as a reference smallest sum of LD recorded since treatment start, appearance of &gt;=1 new lesions, unequivocal progression of existing non-TL, or appearance of &gt;=1 new lesion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-03446962</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03446962</intervention_name>
    <description>PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of stomach cancer

          -  advanced/metastasis solid tumor refractory or intolerant to established therapy

          -  adequate blood chemistry, blood counts and kidney/liver function

          -  willing to participate to study requirements and sign an informed consent document

        Exclusion Criteria:

          -  Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of
             first dose of study medication

          -  excessive toxicities related to prior therapies

          -  pregnant or breastfeeding patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital/Department of Internal Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8471004&amp;StudyName=Asian%20Phase%20I%20Study%20Of%20PF-03446962</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <results_first_submitted>July 16, 2015</results_first_submitted>
  <results_first_submitted_qc>August 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2015</results_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Advanced/Metastatic solid tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PF-03446962 4.5 mg/kg</title>
          <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
        </group>
        <group group_id="P2">
          <title>PF-03446962 7.0 mg/kg</title>
          <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
        </group>
        <group group_id="P3">
          <title>PF-03446962 10.0 mg/kg</title>
          <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participants refused further follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set included all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>PF-03446962 4.5 mg/kg</title>
          <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
        </group>
        <group group_id="B2">
          <title>PF-03446962 7.0 mg/kg</title>
          <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
        </group>
        <group group_id="B3">
          <title>PF-03446962 10.0 mg/kg</title>
          <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="10.9"/>
                    <measurement group_id="B2" value="56.5" spread="12.4"/>
                    <measurement group_id="B3" value="57.7" spread="13.1"/>
                    <measurement group_id="B4" value="57.4" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>The MTD was defined as the highest dose of PF-03446962 associated with the occurrence of Dose Limiting Toxicities (DLTs) in at most 1 of 6 participants with the next higher dose having at least 2/3 or 2/6 participants experiencing DLTs (that is (i.e.) Maximum Administrated Dose). DLT is defined if the participants meets the following criteria during the first 6 weeks of treatment, possibly attributable to PF-03446962. Neutropenia grade 4 (less than [&lt; ])500/cubic millimeter [mm^ 3]) lasting for greater than equal to (&gt;=) 8 days; Febrile Neutropenia &gt;= Grade 3; Neutropenic Infection &gt;= Grade 3; Grade 4 thrombocytopenia (&lt;25,000/mm^3); Grade 3 thrombocytopenia (&lt;50,000/mm^3) with active bleeding; Grade 3 or higher non-hematological toxicity.</description>
        <time_frame>Baseline up to Week 6</time_frame>
        <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962</title>
            <description>PF-03446962 4.5, 7.0 or 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>The MTD was defined as the highest dose of PF-03446962 associated with the occurrence of Dose Limiting Toxicities (DLTs) in at most 1 of 6 participants with the next higher dose having at least 2/3 or 2/6 participants experiencing DLTs (that is (i.e.) Maximum Administrated Dose). DLT is defined if the participants meets the following criteria during the first 6 weeks of treatment, possibly attributable to PF-03446962. Neutropenia grade 4 (less than [&lt; ])500/cubic millimeter [mm^ 3]) lasting for greater than equal to (&gt;=) 8 days; Febrile Neutropenia &gt;= Grade 3; Neutropenic Infection &gt;= Grade 3; Grade 4 thrombocytopenia (&lt;25,000/mm^3); Grade 3 thrombocytopenia (&lt;50,000/mm^3) with active bleeding; Grade 3 or higher non-hematological toxicity.</description>
          <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>mg/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase-2 Dose (RP2D)</title>
        <description>RP2D was determined by a comprehensive assessments based on all the safety data, efficacy data, pharmacokinetics profile and biomarker data using blood and tumor samples.</description>
        <time_frame>Baseline up to 28 days after last dose of study medication</time_frame>
        <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962</title>
            <description>PF-03446962 4.5, 7.0 or 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase-2 Dose (RP2D)</title>
          <description>RP2D was determined by a comprehensive assessments based on all the safety data, efficacy data, pharmacokinetics profile and biomarker data using blood and tumor samples.</description>
          <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication.</population>
          <units>mg/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious adverse events (non-SAEs).</description>
        <time_frame>Baseline up to 28 days after last dose</time_frame>
        <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious adverse events (non-SAEs).</description>
          <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity</title>
        <description>Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity; Grade 1 (Mild Adverse Event), Grade 2 (Moderate Adverse Event), Grade 3 (Severe Adverse Event), Grade 4 (Life- Threatening or Disabling Adverse Event), Grade 5 (Death Related to Adverse Event).</description>
        <time_frame>Baseline up to 28 days after last dose</time_frame>
        <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity</title>
          <description>Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity; Grade 1 (Mild Adverse Event), Grade 2 (Moderate Adverse Event), Grade 3 (Severe Adverse Event), Grade 4 (Life- Threatening or Disabling Adverse Event), Grade 5 (Death Related to Adverse Event).</description>
          <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (non-SAEs). Relatedness to study drug was assessed based on investigator's discretion.</description>
        <time_frame>Baseline up to 28 days after last dose</time_frame>
        <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (non-SAEs). Relatedness to study drug was assessed based on investigator's discretion.</description>
          <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Abnormalities</title>
        <description>Laboratory abnormalities were segregated into hematology, chemistry, coagulation and urinalysis test. It had been graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) into Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Life-threatening). Participants with abnormality of any of these grades are reported.</description>
        <time_frame>Baseline up to 28 days after last dose</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities</title>
          <description>Laboratory abnormalities were segregated into hematology, chemistry, coagulation and urinalysis test. It had been graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) into Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (Life-threatening). Participants with abnormality of any of these grades are reported.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte count increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cells (WBC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase (ALT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase (AST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercalcemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypernatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoalbuminemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocalcemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin time (PT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT International Normalized Ratio(INR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax)</title>
        <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
        <population>Pharmacokinetic (PK) parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax)</title>
          <population>Pharmacokinetic (PK) parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89420" spread="47"/>
                    <measurement group_id="O2" value="121100" spread="34"/>
                    <measurement group_id="O3" value="169000" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Serum Trough Concentration (Cmin)</title>
        <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
        <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Serum Trough Concentration (Cmin)</title>
          <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6689" spread="47"/>
                    <measurement group_id="O2" value="14680" spread="22"/>
                    <measurement group_id="O3" value="22940" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
        <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest.</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="47" lower_limit="0.983" upper_limit="8.00"/>
                    <measurement group_id="O2" value="2.00" spread="22" lower_limit="0.900" upper_limit="8.02"/>
                    <measurement group_id="O3" value="1.50" spread="27" lower_limit="0.950" upper_limit="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to 28 Days [AUC (0-28)]</title>
        <description>AUC (0-28)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-28).</description>
        <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
        <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to 28 Days [AUC (0-28)]</title>
          <description>AUC (0-28)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-28).</description>
          <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>nanogram*hour per milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12360000" spread="36"/>
                    <measurement group_id="O2" value="21980000" spread="14"/>
                    <measurement group_id="O3" value="30360000" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</title>
        <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) for drug.</description>
        <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
        <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</title>
          <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) for drug.</description>
          <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12050000" spread="39"/>
                    <measurement group_id="O2" value="20500000" spread="30"/>
                    <measurement group_id="O3" value="26070000" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance (CL)</title>
        <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
        <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
        <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (CL)</title>
          <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
          <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>liter per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01880" spread="31"/>
                    <measurement group_id="O2" value="0.01482" spread="20"/>
                    <measurement group_id="O3" value="NA">Data was not reported if less than 3 participants data was available, as planned.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Vd)</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
        <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
        <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vd)</title>
          <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.</description>
          <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>liter (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.535" spread="23"/>
                    <measurement group_id="O2" value="6.556" spread="23"/>
                    <measurement group_id="O3" value="NA">Data was not analyzed if less than 3 participants were evaluable for the measure, as per planned analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Decay Half-Life (t1/2)</title>
        <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0 (pre dose), 0.5, 1 (right before the end of infusion), 1.5, 2, 5, 8, 24 hours after the start of infusion of the first dose on Day 1; Day 3, 5, 8, 11, 15, 22 of Cycle 1</time_frame>
        <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2)</title>
          <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
          <population>PK parameter analysis population included all participants treated who had at least 1 of the PK parameters of interest. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.58" spread="2.2081"/>
                    <measurement group_id="O2" value="14.16" spread="1.7822"/>
                    <measurement group_id="O3" value="NA">Data was not analyzed if less than 3 participants were evaluable for the measure, as per planned analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soluble Proteins Level</title>
        <description>Soluble proteins related to Activin Receptor-Like Kinase 1 (ALK-1) signaling and angiogenesis signaling including Vascular adhesion molecule (VAM), Monocyte chemotactic protein 1 (MCP-1), Angiopoietin 2, Tear intercellular adhesive molecule 1 (ICAM-1), Soluble intracellular adhesion molecule 1 (SIAM-1), Soluble vascular adhesion molecule 1 (SVAM-1), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Soluble vascular endothelial growth factor- Receptor 1 (REC 1) (SVEGF-REC 1), Soluble vascular endothelial growth factor- REC 2 (SVEGF-REC 2), Soluble vascular endothelial growth factor- REC 3 (SVEGF-REC 3), Bone morphogenetic protein-9 (BMP-9), Endoglin, Transforming growth factor- beta 1 (TGF- Beta 1), Placental growth factor (PGF) was evaluated.</description>
        <time_frame>Baseline, Day 1, 0 hour (H), 6 H Cycle 1 Day 1, Day 22 of Cycle 1, Day 1 Cycle 2, Day 1 Cycle 3 and end of treatment (up to cycle 30)</time_frame>
        <population>Biomarker analysis population included all enrolled and treated participants with baseline and on-treatment biomarker sample analyzed. Here “n”= participants who were evaluable for specified biomarker at given time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Soluble Proteins Level</title>
          <description>Soluble proteins related to Activin Receptor-Like Kinase 1 (ALK-1) signaling and angiogenesis signaling including Vascular adhesion molecule (VAM), Monocyte chemotactic protein 1 (MCP-1), Angiopoietin 2, Tear intercellular adhesive molecule 1 (ICAM-1), Soluble intracellular adhesion molecule 1 (SIAM-1), Soluble vascular adhesion molecule 1 (SVAM-1), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Soluble vascular endothelial growth factor- Receptor 1 (REC 1) (SVEGF-REC 1), Soluble vascular endothelial growth factor- REC 2 (SVEGF-REC 2), Soluble vascular endothelial growth factor- REC 3 (SVEGF-REC 3), Bone morphogenetic protein-9 (BMP-9), Endoglin, Transforming growth factor- beta 1 (TGF- Beta 1), Placental growth factor (PGF) was evaluated.</description>
          <population>Biomarker analysis population included all enrolled and treated participants with baseline and on-treatment biomarker sample analyzed. Here “n”= participants who were evaluable for specified biomarker at given time point for each arm, respectively.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAM: Baseline (n=0,1,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="5769662.5">Standard deviation could not be calculated because only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="4529407.4" spread="2147607.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAM: Cycle1/Day1 0H(n=0,1,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="5013301.1">Standard deviation could not be calculated because only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="4834240.9" spread="4649500.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAM: Cycle1/Day1 6H (n=0,1,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="6403610.0">Standard deviation could not be calculated because only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="5787177.6" spread="4880400.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAM: Cycle1/Day22 (n=0,0,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O3" value="6388997.9" spread="3326806.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAM: Cycle2/Day1 (n=0,0,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O3" value="8156950.3" spread="8059603.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAM: Cycle3/Day1 (n=0,1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="3539105.4">Standard deviation could not be calculated because only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="6601473.2" spread="3524102.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAM: End of Treatment (n=0,3,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="10329091.1" spread="1748797.03"/>
                    <measurement group_id="O3" value="5648426.5" spread="1095588.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1049.6" spread="202.58"/>
                    <measurement group_id="O2" value="934.8" spread="444.61"/>
                    <measurement group_id="O3" value="1016.7" spread="341.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="916.9" spread="79.30"/>
                    <measurement group_id="O2" value="911.2" spread="233.53"/>
                    <measurement group_id="O3" value="867.9" spread="345.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1246.8" spread="453.48"/>
                    <measurement group_id="O2" value="1774.5" spread="1150.89"/>
                    <measurement group_id="O3" value="2283.8" spread="1462.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="932.2" spread="241.45"/>
                    <measurement group_id="O2" value="870.5" spread="233.82"/>
                    <measurement group_id="O3" value="1201.5" spread="654.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1202.9" spread="208.51"/>
                    <measurement group_id="O2" value="864.1" spread="188.86"/>
                    <measurement group_id="O3" value="1154.6" spread="741.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="857.5" spread="95.32"/>
                    <measurement group_id="O2" value="916.8" spread="288.98"/>
                    <measurement group_id="O3" value="797.8" spread="403.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="811.3" spread="185.47"/>
                    <measurement group_id="O2" value="1066.0" spread="451.04"/>
                    <measurement group_id="O3" value="1144.0" spread="547.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angioprotein-2: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358.7" spread="183.72"/>
                    <measurement group_id="O2" value="490.5" spread="300.64"/>
                    <measurement group_id="O3" value="730.1" spread="800.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angioprotein-2: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369.9" spread="167.24"/>
                    <measurement group_id="O2" value="439.2" spread="190.70"/>
                    <measurement group_id="O3" value="654.3" spread="686.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angioprotein-2: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282.1" spread="130.38"/>
                    <measurement group_id="O2" value="416.0" spread="239.46"/>
                    <measurement group_id="O3" value="792.7" spread="813.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angioprotein-2: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406.8" spread="234.83"/>
                    <measurement group_id="O2" value="503.4" spread="242.67"/>
                    <measurement group_id="O3" value="1282.8" spread="1901.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angioprotein-2: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.5" spread="122.91"/>
                    <measurement group_id="O2" value="513.6" spread="280.22"/>
                    <measurement group_id="O3" value="752.2" spread="568.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angioprotein-2: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309.1" spread="48.30"/>
                    <measurement group_id="O2" value="510.8" spread="256.27"/>
                    <measurement group_id="O3" value="416.4" spread="514.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angioprotein-2: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.6" spread="154.63"/>
                    <measurement group_id="O2" value="666.1" spread="510.48"/>
                    <measurement group_id="O3" value="1147.2" spread="1452.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICAM-1: Baseline (n=0,1,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="1277073.8">Standard deviation could not be calculated because only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="931954.7" spread="1058110.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICAM-1: Cycle1/Day1 0H (n=0,1,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="878849.0">Standard deviation could not be calculated because only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="844534.8" spread="802742.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICAM-1: Cycle1/Day1 6H (n=0,1,10,)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="806572.4">Standard deviation could not be calculated because only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="915166.4" spread="923611.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICAM-1: Cycle1/Day22(n=0,0,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O3" value="1226089.9" spread="1128415.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICAM-1: Cycle2/Day1 (n=0,0,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O3" value="827621.8" spread="367125.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICAM-1: Cycle3/Day1 (n=0,1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="479439.4">Standard deviation could not be calculated because only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="542607.5" spread="150328.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICAM-1: End of Treatment (n=0,3,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not available as no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="1271075.6" spread="515605.73"/>
                    <measurement group_id="O3" value="1651061.8" spread="2042387.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIAM-1: Baseline (n=4,12,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="701303.4" spread="294804.13"/>
                    <measurement group_id="O2" value="466302.8" spread="309842.34"/>
                    <measurement group_id="O3" value="525958.2" spread="113283.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIAM-1: Cycle1/Day1 0H (n=4,12,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="623840.0" spread="181192.64"/>
                    <measurement group_id="O2" value="504021.3" spread="256755.23"/>
                    <measurement group_id="O3" value="532390.8" spread="180640.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIAM-1: Cycle1/Day1 6H (n=4,12,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="604163.5" spread="214935.46"/>
                    <measurement group_id="O2" value="411628.1" spread="261009.28"/>
                    <measurement group_id="O3" value="569359.0" spread="201989.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIAM-1: Cycle1/Day22 (n=4,12,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668593.1" spread="184915.57"/>
                    <measurement group_id="O2" value="501742.8" spread="320205.39"/>
                    <measurement group_id="O3" value="622325.0" spread="238791.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIAM-1: Cycle2/Day1 (n=3,12,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552736.5" spread="184915.57"/>
                    <measurement group_id="O2" value="501742.8" spread="320205.39"/>
                    <measurement group_id="O3" value="622325.0" spread="238791.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIAM-1: Cycle3/Day1 (n=2,7,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="638075.4" spread="127112.48"/>
                    <measurement group_id="O2" value="598448.3" spread="317579.77"/>
                    <measurement group_id="O3" value="438595.7" spread="166268.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SIAM-1: End of Treatment (n=4,4,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="628177.9" spread="163803.34"/>
                    <measurement group_id="O2" value="464669.7" spread="174245.04"/>
                    <measurement group_id="O3" value="719398.7" spread="231843.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVAM-1: Baseline (n=4,12,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2135238.6" spread="849420.75"/>
                    <measurement group_id="O2" value="3651583.3" spread="2216213.70"/>
                    <measurement group_id="O3" value="2551024.9" spread="595975.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVAM-1: Cycle1/Day1 0H (n=4,12,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2061387.9" spread="858687.41"/>
                    <measurement group_id="O2" value="3583328.2" spread="1998977.25"/>
                    <measurement group_id="O3" value="2620267.2" spread="1001526.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVAM-1: Cycle1/Day1 6H (n=4,12,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2034173.6" spread="756983.20"/>
                    <measurement group_id="O2" value="3576192.6" spread="2751678.60"/>
                    <measurement group_id="O3" value="3071682.9" spread="1447507.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVAM-1: Cycle1/Day22 (n=4,12,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2665272.7" spread="1159532.95"/>
                    <measurement group_id="O2" value="4276947.7" spread="2862681.78"/>
                    <measurement group_id="O3" value="3653830.7" spread="1746452.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVAM-1: Cycle2/Day1 (n=3,12,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1892498.5" spread="68777.63"/>
                    <measurement group_id="O2" value="4628918.3" spread="3257637.40"/>
                    <measurement group_id="O3" value="3574717.1" spread="1661302.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVAM-1: Cycle3/Day1 (n=2,7,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2117070.8" spread="747786.71"/>
                    <measurement group_id="O2" value="4755433.2" spread="2598745.99"/>
                    <measurement group_id="O3" value="2349177.5" spread="638957.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVAM-1: End of Treatment (n=4,4,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3802384.0" spread="2865638.01"/>
                    <measurement group_id="O2" value="3318897.7" spread="1948986.96"/>
                    <measurement group_id="O3" value="3748602.8" spread="1332529.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-A: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429.4" spread="208.76"/>
                    <measurement group_id="O2" value="889.8" spread="1475.25"/>
                    <measurement group_id="O3" value="463.4" spread="425.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-A: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455.4" spread="175.23"/>
                    <measurement group_id="O2" value="595.3" spread="628.14"/>
                    <measurement group_id="O3" value="410.3" spread="419.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-A: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438.6" spread="210.06"/>
                    <measurement group_id="O2" value="631.9" spread="644.09"/>
                    <measurement group_id="O3" value="460.5" spread="344.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-A: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="703.7" spread="416.74"/>
                    <measurement group_id="O2" value="462.8" spread="381.85"/>
                    <measurement group_id="O3" value="529.1" spread="511.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-A: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="941.0" spread="415.59"/>
                    <measurement group_id="O2" value="508.0" spread="406.78"/>
                    <measurement group_id="O3" value="524.7" spread="541.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-A: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="904.2" spread="1051.75"/>
                    <measurement group_id="O2" value="355.7" spread="259.00"/>
                    <measurement group_id="O3" value="373.5" spread="124.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-A: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.2" spread="676.85"/>
                    <measurement group_id="O2" value="491.6" spread="329.84"/>
                    <measurement group_id="O3" value="556.7" spread="740.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-C: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.6" spread="64.88"/>
                    <measurement group_id="O2" value="112.0" spread="91.80"/>
                    <measurement group_id="O3" value="139.9" spread="92.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-C: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.2" spread="62.45"/>
                    <measurement group_id="O2" value="98.2" spread="101.48"/>
                    <measurement group_id="O3" value="95.6" spread="81.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-C: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" spread="52.85"/>
                    <measurement group_id="O2" value="79.3" spread="64.75"/>
                    <measurement group_id="O3" value="104.2" spread="91.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-C: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.0" spread="67.41"/>
                    <measurement group_id="O2" value="94.2" spread="90.41"/>
                    <measurement group_id="O3" value="105.1" spread="92.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-C: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" spread="61.06"/>
                    <measurement group_id="O2" value="93.0" spread="106.58"/>
                    <measurement group_id="O3" value="93.7" spread="96.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-C: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" spread="0.00"/>
                    <measurement group_id="O2" value="82.2" spread="124.89"/>
                    <measurement group_id="O3" value="128.3" spread="116.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-C: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" spread="60.02"/>
                    <measurement group_id="O2" value="93.3" spread="111.24"/>
                    <measurement group_id="O3" value="64.7" spread="68.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-D: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="988.6" spread="208.49"/>
                    <measurement group_id="O2" value="1349.5" spread="1133.71"/>
                    <measurement group_id="O3" value="1176.4" spread="361.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-D: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="941.6" spread="114.91"/>
                    <measurement group_id="O2" value="1323.1" spread="962.53"/>
                    <measurement group_id="O3" value="1059.7" spread="365.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-D: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="881.9" spread="89.36"/>
                    <measurement group_id="O2" value="1341.9" spread="1154.09"/>
                    <measurement group_id="O3" value="1160.3" spread="389.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-D: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="853.9" spread="176.92"/>
                    <measurement group_id="O2" value="1327.6" spread="984.57"/>
                    <measurement group_id="O3" value="1365.8" spread="431.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-D: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="836.2" spread="161.42"/>
                    <measurement group_id="O2" value="1430.0" spread="1203.55"/>
                    <measurement group_id="O3" value="1315.8" spread="527.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-D: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="995.7" spread="263.82"/>
                    <measurement group_id="O2" value="1445.3" spread="1403.28"/>
                    <measurement group_id="O3" value="995.2" spread="443.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF-D: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="809.4" spread="176.66"/>
                    <measurement group_id="O2" value="1494.1" spread="1000.50"/>
                    <measurement group_id="O3" value="1420.1" spread="402.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 1: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.3" spread="29.59"/>
                    <measurement group_id="O2" value="162.3" spread="60.10"/>
                    <measurement group_id="O3" value="228.5" spread="88.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 1: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.0" spread="51.72"/>
                    <measurement group_id="O2" value="1397.1" spread="4204.03"/>
                    <measurement group_id="O3" value="3196.4" spread="10603.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 1: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.9" spread="16.94"/>
                    <measurement group_id="O2" value="177.1" spread="81.20"/>
                    <measurement group_id="O3" value="255.2" spread="95.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 1: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.0" spread="39.82"/>
                    <measurement group_id="O2" value="170.9" spread="93.07"/>
                    <measurement group_id="O3" value="299.4" spread="138.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 1: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447.4" spread="467.46"/>
                    <measurement group_id="O2" value="222.5" spread="142.78"/>
                    <measurement group_id="O3" value="261.0" spread="115.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 1: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.8" spread="29.27"/>
                    <measurement group_id="O2" value="155.5" spread="80.26"/>
                    <measurement group_id="O3" value="192.5" spread="82.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 1: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.7" spread="33.47"/>
                    <measurement group_id="O2" value="234.2" spread="172.30"/>
                    <measurement group_id="O3" value="276.8" spread="227.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 2: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7436.6" spread="1857.86"/>
                    <measurement group_id="O2" value="6888.7" spread="2231.62"/>
                    <measurement group_id="O3" value="8440.8" spread="2437.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 2: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7914.2" spread="2988.27"/>
                    <measurement group_id="O2" value="7026.7" spread="2025.46"/>
                    <measurement group_id="O3" value="7741.2" spread="2133.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 2: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7870.7" spread="3373.09"/>
                    <measurement group_id="O2" value="6586.3" spread="2081.36"/>
                    <measurement group_id="O3" value="8378.4" spread="1904.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 2: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7235.8" spread="2807.65"/>
                    <measurement group_id="O2" value="7069.1" spread="2453.67"/>
                    <measurement group_id="O3" value="8493.1" spread="1844.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 2: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7597.3" spread="3168.18"/>
                    <measurement group_id="O2" value="7245.4" spread="2560.56"/>
                    <measurement group_id="O3" value="7965.4" spread="2421.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 2: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8516.8" spread="3960.15"/>
                    <measurement group_id="O2" value="6827.8" spread="2613.39"/>
                    <measurement group_id="O3" value="8193.9" spread="2074.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 2: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6714.4" spread="2171.59"/>
                    <measurement group_id="O2" value="6908.6" spread="2872.56"/>
                    <measurement group_id="O3" value="8963.3" spread="1366.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 3: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456712.6" spread="63869.92"/>
                    <measurement group_id="O2" value="332957.5" spread="114561.87"/>
                    <measurement group_id="O3" value="434940.1" spread="109510.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 3: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406786.4" spread="11524.53"/>
                    <measurement group_id="O2" value="355960.5" spread="132035.48"/>
                    <measurement group_id="O3" value="407148.7" spread="92393.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 3: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395896.6" spread="61076.24"/>
                    <measurement group_id="O2" value="336962.5" spread="141091.61"/>
                    <measurement group_id="O3" value="416266.6" spread="90886.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 3: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374514.7" spread="33518.13"/>
                    <measurement group_id="O2" value="310883.6" spread="87289.24"/>
                    <measurement group_id="O3" value="454274.1" spread="141305.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 3: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405961.9" spread="34525.64"/>
                    <measurement group_id="O2" value="317659.8" spread="79198.45"/>
                    <measurement group_id="O3" value="450339.2" spread="162644.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 3: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421505.5" spread="23124.80"/>
                    <measurement group_id="O2" value="289021.4" spread="73419.94"/>
                    <measurement group_id="O3" value="311026.0" spread="93213.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVEGF-REC 3: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345569.6" spread="19964.62"/>
                    <measurement group_id="O2" value="307319.1" spread="99790.00"/>
                    <measurement group_id="O3" value="434549.1" spread="95476.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMP-9: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="4.77"/>
                    <measurement group_id="O2" value="64.5" spread="155.34"/>
                    <measurement group_id="O3" value="24.8" spread="18.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMP-9: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="5.00"/>
                    <measurement group_id="O2" value="47.3" spread="114.00"/>
                    <measurement group_id="O3" value="22.0" spread="12.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMP-9: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="8.95"/>
                    <measurement group_id="O2" value="58.6" spread="130.87"/>
                    <measurement group_id="O3" value="33.4" spread="15.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMP-9: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="6.39"/>
                    <measurement group_id="O2" value="49.8" spread="121.48"/>
                    <measurement group_id="O3" value="25.7" spread="12.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMP-9: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="5.01"/>
                    <measurement group_id="O2" value="61.5" spread="158.39"/>
                    <measurement group_id="O3" value="24.7" spread="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMP-9: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="16.33"/>
                    <measurement group_id="O2" value="84.8" spread="194.91"/>
                    <measurement group_id="O3" value="25.2" spread="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMP-9: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="6.09"/>
                    <measurement group_id="O2" value="123.3" spread="259.17"/>
                    <measurement group_id="O3" value="47.0" spread="70.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endoglin: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22292.9" spread="7065.67"/>
                    <measurement group_id="O2" value="26312.5" spread="8345.99"/>
                    <measurement group_id="O3" value="31096.0" spread="7553.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endoglin: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21148.2" spread="4493.48"/>
                    <measurement group_id="O2" value="26514.1" spread="4171.10"/>
                    <measurement group_id="O3" value="29437.1" spread="8796.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endoglin: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20252.9" spread="3093.23"/>
                    <measurement group_id="O2" value="24385.0" spread="7947.74"/>
                    <measurement group_id="O3" value="29898.7" spread="7743.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endoglin: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20304.6" spread="3085.27"/>
                    <measurement group_id="O2" value="28106.4" spread="6786.70"/>
                    <measurement group_id="O3" value="39570.2" spread="11857.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endoglin: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18974.4" spread="2212.35"/>
                    <measurement group_id="O2" value="29533.7" spread="8065.27"/>
                    <measurement group_id="O3" value="35585.1" spread="8558.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endoglin: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20441.2" spread="5168.88"/>
                    <measurement group_id="O2" value="28063.4" spread="6794.28"/>
                    <measurement group_id="O3" value="33439.4" spread="7464.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endoglin: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21756.8" spread="5825.18"/>
                    <measurement group_id="O2" value="31653.3" spread="9829.63"/>
                    <measurement group_id="O3" value="33159.2" spread="10674.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGF-Beta1: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439154.4" spread="194384.01"/>
                    <measurement group_id="O2" value="288057.2" spread="95964.14"/>
                    <measurement group_id="O3" value="264779.6" spread="245081.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGF-Beta1: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="420293.6" spread="154286.55"/>
                    <measurement group_id="O2" value="228313.8" spread="101963.47"/>
                    <measurement group_id="O3" value="187730.4" spread="173444.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGF-Beta1: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361727.2" spread="195371.45"/>
                    <measurement group_id="O2" value="240430.8" spread="97194.19"/>
                    <measurement group_id="O3" value="194814.7" spread="173849.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGF-Beta1: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322848.7" spread="122214.82"/>
                    <measurement group_id="O2" value="248764.0" spread="105171.95"/>
                    <measurement group_id="O3" value="169310.4" spread="187249.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGF-Beta1: Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="485627.2" spread="145104.03"/>
                    <measurement group_id="O2" value="253554.9" spread="97795.74"/>
                    <measurement group_id="O3" value="214255.5" spread="269963.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGF-Beta1: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355810.5" spread="308789.78"/>
                    <measurement group_id="O2" value="231920.2" spread="128882.61"/>
                    <measurement group_id="O3" value="280515.6" spread="270982.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TGF-Beta1: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292378.4" spread="154058.94"/>
                    <measurement group_id="O2" value="235871.6" spread="129631.54"/>
                    <measurement group_id="O3" value="249663.6" spread="300797.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGF: Baseline (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="16.56"/>
                    <measurement group_id="O2" value="10.7" spread="4.03"/>
                    <measurement group_id="O3" value="9.6" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGF: Cycle1/Day1 0H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="13.03"/>
                    <measurement group_id="O2" value="12.7" spread="4.67"/>
                    <measurement group_id="O3" value="9.5" spread="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGF: Cycle1/Day1 6H (n=4,13,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="9.90"/>
                    <measurement group_id="O2" value="14.8" spread="7.35"/>
                    <measurement group_id="O3" value="14.8" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGF: Cycle1/Day22 (n=4,12,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="8.19"/>
                    <measurement group_id="O2" value="9.6" spread="3.28"/>
                    <measurement group_id="O3" value="9.9" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGF:Cycle2/Day1 (n=3,12,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="1.25"/>
                    <measurement group_id="O2" value="10.1" spread="3.77"/>
                    <measurement group_id="O3" value="9.2" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGF: Cycle3/Day1 (n=2,8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="0.28"/>
                    <measurement group_id="O2" value="8.2" spread="2.60"/>
                    <measurement group_id="O3" value="6.9" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGF: End of Treatment (n=4,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="8.28"/>
                    <measurement group_id="O2" value="7.9" spread="2.43"/>
                    <measurement group_id="O3" value="8.6" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Human Anti-Human Antibody (HAHA)</title>
        <description>HAHA analysis was performed using validated, sensitive and specific chemiluminescence enzyme-linked immunosorbent assay (ELISA) methodology.</description>
        <time_frame>Baseline, Post-dose (Day 1 of every Cycle up to 28 days after last dose) up to Cycle 30</time_frame>
        <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Human Anti-Human Antibody (HAHA)</title>
          <description>HAHA analysis was performed using validated, sensitive and specific chemiluminescence enzyme-linked immunosorbent assay (ELISA) methodology.</description>
          <population>Safety analysis set included all enrolled participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1" spread="2147607.09"/>
                    <measurement group_id="O3" value="3" spread="2071432.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" spread="4649500.22"/>
                    <measurement group_id="O3" value="0" spread="4411233.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Best Overall Response (BOR)</title>
        <description>Number of participants with best overall response according to Response Evaluation Criteria in Solid Tumors (RECIST); Complete response (CR): disappearance of all lesions, Pathological lymph nodes’ reduction in short axis (SA) to less than (&lt;)10 millimeter (mm); Partial response (PR): greater than equal to (&gt;=) 30% decrease in sum of longest dimensions (LD) of Target Lesions (TL) taking reference baseline sum LD; Progressive disease (PD):&gt;=20% (&gt;= 5 mm increase) increase sum of LD of TL taking as a reference smallest sum of LD recorded since treatment start, appearance of &gt;=1 new lesions, unequivocal progression of existing non-TL, or appearance of &gt;=1 new lesion; Stable disease (SD): insufficient shrinkage to qualify for PR, insufficient increase to qualify for PD taking reference smallest sum of the LD since treatment start. Confirmed response=that persist at least 4 weeks after initial documentation.</description>
        <time_frame>Baseline, thereafter every 6 weeks up to end of treatment (up to Cycle 30)</time_frame>
        <population>Response evaluable population included all enrolled participants with measurable disease who received at least 1 dose of PF-03446962 and had an adequate baseline tumor assessment. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Best Overall Response (BOR)</title>
          <description>Number of participants with best overall response according to Response Evaluation Criteria in Solid Tumors (RECIST); Complete response (CR): disappearance of all lesions, Pathological lymph nodes’ reduction in short axis (SA) to less than (&lt;)10 millimeter (mm); Partial response (PR): greater than equal to (&gt;=) 30% decrease in sum of longest dimensions (LD) of Target Lesions (TL) taking reference baseline sum LD; Progressive disease (PD):&gt;=20% (&gt;= 5 mm increase) increase sum of LD of TL taking as a reference smallest sum of LD recorded since treatment start, appearance of &gt;=1 new lesions, unequivocal progression of existing non-TL, or appearance of &gt;=1 new lesion; Stable disease (SD): insufficient shrinkage to qualify for PR, insufficient increase to qualify for PD taking reference smallest sum of the LD since treatment start. Confirmed response=that persist at least 4 weeks after initial documentation.</description>
          <population>Response evaluable population included all enrolled participants with measurable disease who received at least 1 dose of PF-03446962 and had an adequate baseline tumor assessment. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" spread="2147607.09"/>
                    <measurement group_id="O3" value="0" spread="2071432.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" spread="4649500.22"/>
                    <measurement group_id="O3" value="0" spread="4411233.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4" spread="8059603.45"/>
                    <measurement group_id="O3" value="4" spread="8059603.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7" spread="3524102.00"/>
                    <measurement group_id="O3" value="13" spread="3259456.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic Deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1748797.03"/>
                    <measurement group_id="O2" value="0" spread="1095588.29"/>
                    <measurement group_id="O3" value="1" spread="2725448.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indeterminate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Benefit Response (CBR)</title>
        <description>Number of participant with clinical benefit response (CBR): CBR was defined as CR, PR, SD &gt;12 weeks, SD&lt;12weeks or PD according to RECIST criteria; Complete response (CR): disappearance of all lesions, Pathological lymph nodes’ reduction in short axis (SA) to &lt;10 mm; Partial response (PR): &gt;=30% decrease in sum of longest dimensions (LD) of Target Lesions (TL) taking reference baseline sum LD; Progressive disease (PD):&gt;=20% (&gt;= 5 mm increase) increase sum of LD of TL taking as a reference smallest sum of LD recorded since treatment start, appearance of &gt;=1 new lesions, unequivocal progression of existing non-TL, or appearance of &gt;=1 new lesion; Stable disease (SD): insufficient shrinkage to qualify for PR, insufficient increase to qualify for PD taking reference smallest sum of the LD since treatment start.</description>
        <time_frame>Baseline, thereafter every 6 weeks up to end of treatment (up to Cycle 30)</time_frame>
        <population>Response evaluable population included all enrolled participants with measurable disease who received at least 1 dose of PF-03446962 and had an adequate baseline tumor assessment. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Benefit Response (CBR)</title>
          <description>Number of participant with clinical benefit response (CBR): CBR was defined as CR, PR, SD &gt;12 weeks, SD&lt;12weeks or PD according to RECIST criteria; Complete response (CR): disappearance of all lesions, Pathological lymph nodes’ reduction in short axis (SA) to &lt;10 mm; Partial response (PR): &gt;=30% decrease in sum of longest dimensions (LD) of Target Lesions (TL) taking reference baseline sum LD; Progressive disease (PD):&gt;=20% (&gt;= 5 mm increase) increase sum of LD of TL taking as a reference smallest sum of LD recorded since treatment start, appearance of &gt;=1 new lesions, unequivocal progression of existing non-TL, or appearance of &gt;=1 new lesion; Stable disease (SD): insufficient shrinkage to qualify for PR, insufficient increase to qualify for PD taking reference smallest sum of the LD since treatment start.</description>
          <population>Response evaluable population included all enrolled participants with measurable disease who received at least 1 dose of PF-03446962 and had an adequate baseline tumor assessment. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS was defined as the time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Months) = (first event date minus randomization or the first dose date plus 1) divided by 30.44). PFS was calculated using the median, and 95% Confidence Intervals (CIs) and Progressive disease (PD):&gt;=20% (&gt;= 5 mm increase) increase sum of LD of TL taking as a reference smallest sum of LD recorded since treatment start, appearance of &gt;=1 new lesions, unequivocal progression of existing non-TL, or appearance of &gt;=1 new lesion.</description>
        <time_frame>Baseline, thereafter every 6 weeks up to end of treatment (up to Cycle 30)</time_frame>
        <population>Response evaluable population included all enrolled participants with measurable disease who received at least 1 dose of PF-03446962 and had an adequate baseline tumor assessment. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-03446962 4.5 mg/kg</title>
            <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O2">
            <title>PF-03446962 7.0 mg/kg</title>
            <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
          <group group_id="O3">
            <title>PF-03446962 10.0 mg/kg</title>
            <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS was defined as the time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Months) = (first event date minus randomization or the first dose date plus 1) divided by 30.44). PFS was calculated using the median, and 95% Confidence Intervals (CIs) and Progressive disease (PD):&gt;=20% (&gt;= 5 mm increase) increase sum of LD of TL taking as a reference smallest sum of LD recorded since treatment start, appearance of &gt;=1 new lesions, unequivocal progression of existing non-TL, or appearance of &gt;=1 new lesion.</description>
          <population>Response evaluable population included all enrolled participants with measurable disease who received at least 1 dose of PF-03446962 and had an adequate baseline tumor assessment. Here “N” (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.2" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.8" spread="2147607.09" lower_limit="1.3" upper_limit="5.6"/>
                    <measurement group_id="O3" value="1.3" spread="2071432.82" lower_limit="1.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subject, or one subject may have experienced both a serious and non-serious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>PF-03446962 4.5 mg/kg</title>
          <description>PF-03446962 4.5 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
        </group>
        <group group_id="E2">
          <title>PF-03446962 7.0 mg/kg</title>
          <description>PF-03446962 7.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
        </group>
        <group group_id="E3">
          <title>PF-03446962 10.0 mg/kg</title>
          <description>PF-03446962 10.0 mg/kg intravenous infusion over 1 hour on Day 1 of each cycle. Cycle 1 was of 28 days duration and all subsequent cycles were of 14 days duration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Injection site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pseudofolliculitis barbae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Eschar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Liver carcinoma ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Atonic urinary bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Designation of primary and secondary endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

